Ocular Therapeutix chief scientific officer sells $21,712 in stock

BEDFORD, MA—Jeffrey S. Heier, the Chief Scientific Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), has recently sold shares of the company’s common stock. According to a recent SEC filing, Heier sold 3,024 shares on May 23, 2025, at a weighted average price of $7.18 per share, totaling approximately $21,712. The transaction comes as the stock trades near $6.94, down from its 52-week high of $11.78. According to InvestingPro data, the company currently maintains a market capitalization of $1.1 billion and carries a "Fair" overall financial health score.

The sale was executed under a pre-arranged trading plan, established on April 9, 2024, to cover tax obligations associated with the vesting of restricted stock units. This transaction was not a discretionary trade, as it was part of a durable automatic sale instruction to satisfy tax withholding requirements. With analysts maintaining a strong buy consensus and setting price targets between $14 and $22, InvestingPro subscribers can access comprehensive insider trading analysis and 8 additional key insights about OCUL’s financial position.

Following this transaction, Heier holds 262,974 shares of Ocular Therapeutix directly.

In other recent news, Ocular Therapeutix reported first-quarter 2025 earnings that did not meet analyst expectations. The company’s revenue was $10.6 million, falling short of the anticipated $17.4 million, and diluted earnings per share were $(0.38), below the projected $(0.30). The revenue decline was largely due to changes in pricing strategies and stocking patterns, as well as the inclusion of its DEXTENZA product in Medicare’s Merit-based Incentive Payment System for 2025. Despite these financial results, Ocular Therapeutix maintains a strong financial position with approximately $350 million in cash and equivalents, expected to sustain operations until 2028.

Raymond (NSE:RYMD) James analyst Dane Leone reiterated a Strong Buy rating for Ocular Therapeutix, citing the potential of its product candidate Axpaxli and the strategic design of its pivotal program. The company is making progress in its clinical programs, with the SOL-1 Phase 3 trial for Axpaxli on track for topline data in the first quarter of 2026. Enrollment in the SOL-R Phase 3 trial remains robust, and upcoming study initiations for NPDR and DME are planned. Ocular Therapeutix anticipates net product revenue to rise in the remaining quarters of 2025 as adjustments to recent changes are made and sales efforts increase.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.